Claims
- 1. A compound of the formula whereinX is —O—, —S—, —NH— or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino; (R1) is —CR24R27—(CR23R24)n—CR24R27— where n is 0, 1, 2, or 3; or —CHR24—CH═CH—CHR24—, —CHR24—C≡C—C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—C≡C—CR23R24—CHR24—, or —CHR24—CR23R24—C≡C—CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy, (C1-C18)alkoxy, aryloxy, aryl (C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy (C1-C6)alkyl, (C1-C18)alkoxy (C1-C6)alkyl, aryl (C1-C18)alkyloxy (C1-C6)alkyl, (C1-C18)alkanoyloxy (C1-C6)alkyl, or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen, and p is as previously defined; and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy (C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl (C1-C6)alkyloxy, aryl (C1-C18)alkyloxy (C1-C6)alkyl, (C1-C18)alkanoyloxy (C1-C6)alkyl, or whereZ1 is as previously defined, and p is as previously defined; R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; with the proviso that R23 is not hydrogen, (C1-C18) linear alkyl, phenyl, or when R27 is hydrogen and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, or with the proviso that R24 is not hydrogen, (C1-C18)linear alkyl, phenyl, or when R27 is hydrogen and n is 0; or when R27 is hydrogen and R23 is hydrogen, (C1-C18)linear alkyl, phenyl, or or when R1 is —CHR24—CH═CH—CHR24— or —CHR24—C≡C—CHR24—;R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, —C(═O)-alkyl, —C(═O)—O-alkyl, —C(═O)-aryl, —C(═O)-heteroaryl, —CH(OR7)-alkyl, —C(═W)-alkyl, —C(═W)-aryl, or —C(═W)-heteroaryl; where alkyl is (C1-C18)alkyl; aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is where Q3 is —O—, —S—, —NH—, or —CH═N—; W is CH2 or CHR8 or N—R9; R7 is hydrogen, lower alkyl, or alkanoyl; R8 is lower alkyl; R9 is hydroxy, lower alkoxy, or —NHR10; and R10 is hydrogen, lower alkyl, C1-C3 acyl, aryl, —C(═O)-aryl or —C(═O)-heteroaryl, where aryl and heteroaryl are as defined above; and m is 1, 2, or 3; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 2. The compound of claim 1, wherein X is —N(R2)—.
- 3. The compound of claim 1, wherein R2 is (C2-C18)alkanoyl or (C1-C18)alkoxycarbonyl.
- 4. The compound of claim 1, wherein (R1) is —CH2CH(OH)CH2— or —CH2CH[OC(═O)(C1-C18)alkyl]CH2—.
- 5. The compound of claim 1, wherein each R is independently selected from the group consisting of hydrogen, (C1-C6)alkoxy, and (C2-C18)alkanoyl; and m is 1 or 2.
- 6. The compound of claim 1, wherein X is —O—.
- 7. An antipsychotic composition, which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier.
- 8. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 1.
- 9. An analgesic composition, which comprises the compound of claim 1 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier.
- 10. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 1.
- 11. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1, wherein the compound contains a hydroxy group, an amino group, or a nitrogen at the 1-position of an indazole ring, which has been acylated.
- 12. The depot pharmaceutical composition of claim 11, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group.
- 13. The composition of claim 11, which contains a pharmaceutically acceptable oil.
- 14. The composition of claim 13, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 15. The composition of claim 12, which contains a pharmaceutically acceptable oil.
- 16. The composition of claim 15, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 17. A method of providing a long-acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 11 sufficient to produce a long-acting antipsychotic effect.
- 18. A method of providing a long-acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 12 sufficient to produce a long-acting antispsychotic effect.
- 19. A method of providing a long-acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 16 sufficient to produce a long-acting antipsychotic effect.
- 20. A compound of the formula whereinX is —O—, —S—, —NH— or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 2; Y is lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino when X is —S—, —NH—, or —N(R2)—; Y is lower alkyl, trifluoromethyl, nitro, or amino when X is O—; (R1) is —CR24R27—(CR23R24)n—CR24R27— where n is 0, 1, 2, or 3; or —CH24—CH═CH—CHR24—, —CHR24—C≡C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—C≡C—CR23R24—CHR24—, or —CHR24—CR23R24—C≡C—CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy,(C1-C18)alkoxy, aryloxy, aryl (C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy (C1-C6)alkyl, (C1-C18)alkoxy (C1-C6)alkyl, aryl (C1-C18)alkyloxy (C1-C6)alkyl, (C1-C18)alkanoyloxy (C1-C6)alkyl, or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen, and p is as previously defined; and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy (C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl (C1-C6)alkyloxy, aryl (C1-C18)alkyloxy (C1-C6)alkyl, (C1-C18)alkanoyloxy (C1-C6)alkyl, or whereZ1 is as previously defined, and p is as previously defined; R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, —(═O)-alkyl, —C(═O)—O-alkyl, —C(═))-aryl, —C(═O)-heteroaryl, —CH(OR7)-alkyl, —C(═W)-alkyl, —C(═W)-aryl, or —C(═W)-heteroaryl; where alkyl is (C1-C18)alkyl; aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is where Q3 is —O—, —S—, —NH—, or —CH═N—; W is CH2 or CHR8 or N—R9; R7 is hydrogen, lower alkyl, or alkanoyl; R8 is lower alkyl; R9 is hydroxy, lower alkoxy, or —NHR10; and R10 is hydrogen, lower alkyl, C1-C3 acyl, aryl, —C(═O)-aryl or —C(═O)-heteroaryl, where aryl and heteroaryl are as defined above; and m is 1, 2, or 3; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; with the proviso that X is not —S— when R, R23, R24, and R27 are H; all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 21. The compound of claim 20, wherein X is —O—.
- 22. An antipsychotic composition, which comprises the compound of claim 20 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier.
- 23. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 20.
- 24. An analgesic composition, which comprises the compound of claim 20 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier.
- 25. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 20.
- 26. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 20, wherein the compound contains a hydroxy group, an amino group, or a nitrogen at the 1-position of an indazole ring, which has been acylated.
- 27. The depot pharmaceutical composition of claim 26, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group.
- 28. The composition of claim 26, which contains a pharmaceutically acceptable oil.
- 29. The composition of claim 28, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 30. The composition of claim 27, which contains a pharmaceutically acceptable oil.
- 31. The composition of claim 30, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 32. A method of providing a long-acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 26 sufficient to produce a long-acting antipsychotic effect.
- 33. A method of providing a long-acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 24 sufficient to produce a long-acting antipsychotic effect.
- 34. A method of providing a long-acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 31 sufficient to produce a long-acting antipsychotic effect.
- 35. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the formula: whereinX is —O—, —S—, —NH— or —N(R2)—; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy, or halogen when p is 2 and X is —O—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; (R1) is R20, R21, or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4 or 5; R21 is —CH2—CH═CH—CH2—, —CH2—C≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2—CH2—CH═CH—CH2—, —CH2—C≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, —C(═O)-alkyl, —C(═O)—O-alkyl, —C(═O)-aryl, —C(═O)-heteroaryl, —CH(OR7)-alkyl, —C(═W)-alkyl, —C(═W)-aryl, or —C(═W)-heteroaryl; where alkyl is (C1-C18)alkyl; aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is where Q3 is —O—, —S—, —NH—, or —CH═N—; W is CH2 or CHR8 or N—R9; R7 is hydrogen, lower alkyl, or alkanoyl; R8 is lower alkyl; R9 is hydroxy, lower alkoxy, or —NHR10; and R10 is hydrogen, lower alkyl, C1-C3 acyl, aryl, —C(═O)-aryl or —C(═O)-heteroaryl, where aryl and heteroaryl are as defined above; and m is 1, 2, or 3; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; wherein the compound contains an acylated hydroxy group, or an acylated amino group, and further wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group; all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 36. The depot pharmaceutical composition of claim 35, which contains a pharmaceutically acceptable oil.
- 37. The depot pharmaceutical composition of claim 36, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 38. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the depot pharmaceutical composition of claim 37 sufficient to produce a long acting antipsychotic effect.
- 39. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the depot pharmaceutical composition of claim 35 sufficient to produce a long acting antipsychotic effect.
CROSS-REFERENCE TO RELATED APPLICATION
This is a division of application Ser. No. 08/468,611, filed Jun. 6, 1995, which is a division of Ser. No. 08/329,000, filed Oct. 25, 1994, now U.S. Pat. No. 5,776,963, which is a CIP of Ser. No. 08/144,265, filed Oct. 28, 1993, now abandoned. The entire disclosure of these applications is relied upon and incorporated by reference herein.
US Referenced Citations (15)
Foreign Referenced Citations (20)
Number |
Date |
Country |
353 0089 |
Mar 1986 |
DE |
2 503 816 |
Jul 1975 |
DK |
0 261 688 |
Mar 1980 |
EP |
0 013 612 |
Jul 1980 |
EP |
0 135 781 |
Apr 1985 |
EP |
0 196 096 |
Oct 1986 |
EP |
0 302 423 |
Feb 1989 |
EP |
0 314 098 |
May 1989 |
EP |
0 329 168 |
Aug 1989 |
EP |
0 357 134 |
Aug 1989 |
EP |
0 353 821 |
Feb 1990 |
EP |
0 398 425 |
Nov 1990 |
EP |
0 402 644 |
Dec 1990 |
EP |
0 464 846 |
Jan 1992 |
EP |
0 542 136 A1 |
May 1992 |
EP |
2 163 432 |
Feb 1986 |
GB |
WO 9316703 |
Aug 1985 |
WO |
WO 9309102 |
May 1993 |
WO |
WO 9316073 |
Aug 1993 |
WO |
WO 9418196 |
Aug 1994 |
WO |
Non-Patent Literature Citations (1)
Entry |
Fuller, R. W., Drugs Acting on Serotonergic Neuronal Systems, Biology of Serotonergic Transmission, John Wiley & Sons Ltd., 1982, pp. 221-247. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/144265 |
Oct 1993 |
US |
Child |
08/329000 |
|
US |